Phio Pharmaceuticals (PHIO) Competitors $1.29 -0.02 (-1.53%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.32 +0.03 (+2.71%) As of 03/28/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. ESLA, RVPH, XCUR, NRXP, LVTX, INKT, GBIO, CASI, CLNN, and OVIDShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Estrella Immunopharma (ESLA), Reviva Pharmaceuticals (RVPH), Exicure (XCUR), NRx Pharmaceuticals (NRXP), LAVA Therapeutics (LVTX), MiNK Therapeutics (INKT), Generation Bio (GBIO), CASI Pharmaceuticals (CASI), Clene (CLNN), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Estrella Immunopharma Reviva Pharmaceuticals Exicure NRx Pharmaceuticals LAVA Therapeutics MiNK Therapeutics Generation Bio CASI Pharmaceuticals Clene Ovid Therapeutics Estrella Immunopharma (NASDAQ:ESLA) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations. Which has stronger earnings and valuation, ESLA or PHIO? Estrella Immunopharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.65Phio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.12 Does the media refer more to ESLA or PHIO? In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.89 beat Phio Pharmaceuticals' score of 1.87 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Very Positive Phio Pharmaceuticals Very Positive Does the MarketBeat Community favor ESLA or PHIO? Phio Pharmaceuticals received 36 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 63.79% of users gave Phio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEstrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo VotesPhio PharmaceuticalsOutperform Votes3763.79% Underperform Votes2136.21% Do institutionals & insiders have more ownership in ESLA or PHIO? 0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ESLA or PHIO more profitable? Phio Pharmaceuticals' return on equity of -134.57% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Phio Pharmaceuticals N/A -134.57%-108.39% Do analysts rate ESLA or PHIO? Estrella Immunopharma currently has a consensus target price of $16.00, indicating a potential upside of 1,585.99%. Phio Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 210.08%. Given Estrella Immunopharma's higher possible upside, equities research analysts plainly believe Estrella Immunopharma is more favorable than Phio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ESLA or PHIO? Estrella Immunopharma has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. SummaryEstrella Immunopharma and Phio Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Remove Ads Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.02M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E Ratio-0.127.1723.4118.71Price / SalesN/A218.12387.8590.69Price / CashN/A65.6738.1734.64Price / Book0.076.396.894.23Net Income-$10.83M$142.12M$3.20B$247.26M7 Day PerformanceN/A-5.09%-3.01%-2.21%1 Month Performance-9.15%-7.52%1.55%-5.74%1 Year Performance-78.92%-11.03%9.37%-0.80% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.9212 of 5 stars$1.29-1.5%$4.00+210.1%-78.9%$9.02MN/A-0.1210Positive NewsESLAEstrella Immunopharma2.4524 of 5 stars$0.99-2.0%$16.00+1,516.5%-23.5%$35.81MN/A-3.81N/APositive NewsRVPHReviva Pharmaceuticals4.2185 of 5 stars$1.07+2.9%$11.40+965.4%-73.3%$35.78MN/A-0.965Short Interest ↓XCURExicure1.2541 of 5 stars$13.57-3.4%N/A+2,225.9%$35.36M$500,000.00-6.5650Short Interest ↑News CoverageGap DownNRXPNRx Pharmaceuticals2.592 of 5 stars$2.07-0.5%$31.67+1,429.8%-95.7%$35.02MN/A-0.972LVTXLAVA Therapeutics2.4827 of 5 stars$1.30flat$3.17+143.6%-61.3%$34.19M$7.35M-1.2660Earnings ReportShort Interest ↓News CoverageINKTMiNK Therapeutics2.4109 of 5 stars$8.57-5.8%$37.50+337.6%-0.6%$33.99MN/A-2.2030GBIOGeneration Bio4.2936 of 5 stars$0.50-1.5%$7.33+1,379.7%-89.5%$33.21M$19.89M-0.23150Short Interest ↓Positive NewsCASICASI Pharmaceuticals4.3255 of 5 stars$2.12-4.1%$6.00+183.0%-40.3%$32.85M$22.06M-0.95180Analyst ForecastShort Interest ↓Positive NewsCLNNClene3.4855 of 5 stars$3.92-5.3%$55.25+1,309.4%-62.2%$32.64M$421,000.00-0.74100Earnings ReportShort Interest ↓Analyst RevisionNews CoverageGap UpOVIDOvid Therapeutics4.5059 of 5 stars$0.44+4.5%$3.03+582.7%-88.5%$31.58M$566,000.00-0.9560Analyst Revision Remove Ads Related Companies and Tools Related Companies ESLA Competitors RVPH Competitors XCUR Competitors NRXP Competitors LVTX Competitors INKT Competitors GBIO Competitors CASI Competitors CLNN Competitors OVID Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHIO Stock Free PHIO Stock Alerts